menu
    • menu
    [{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"ProLectin-I","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioxytran \/ Inapplicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Alke Research Private Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Alke Research Private Limited","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Alke Research Private Limited"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Inapplicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Inapplicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Inapplicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Triton Funds","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Triton Funds","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Triton Funds"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Triton Funds","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Triton Funds","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Triton Funds"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BXT-10","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bioxytran \/ Inapplicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"BXT-25","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bioxytran \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bioxytran \/ Undisclosed"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"BXT-25","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bioxytran \/ Inapplicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Bioxytran

    Menu

    Bioxytran

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M

                            Details : ProLectin M (galactomannan) is a novel substance that is given orally to individuals who havean infection with Sars-CoV-2.

                            Product Name : ProLectin-M

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 12, 2025

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Triton Funds

                            Deal Size : $1.6 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development

                            Details : The net proceeds will used to suport the clinical development of company's lead product ProLectin M (Galactomannan C), which is being evaluated for the treatment of Covid-19 infections.

                            Product Name : ProLectin M

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 22, 2025

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Triton Funds

                            Deal Size : $1.6 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

                            Details : ProLectin-M (galactomannan) is a precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus. It is being evaluated for COVID-19.

                            Product Name : ProLectin-M

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 21, 2024

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Triton Funds

                            Deal Size : $0.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment

                            Details : The proceeds will help to start the dosage optimization study for mild to moderate COVID-19, which has already received the regulatory approval to proceed with dosing of ProLectin-M, an oral galectin antagonist that prevents the entry of the SARS-CoV-2 v...

                            Product Name : ProLectin-M

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 06, 2023

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Triton Funds

                            Deal Size : $0.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials

                            Details : ProLectin-M (galactomannan) is a chewable polysaccharide tablet for the treatment of mild to moderate and early stage COVID-19 Patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.

                            Product Name : ProLectin-M

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 24, 2023

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Alke Research Private Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients

                            Details : ProLectin-M (galactomannan) is a chewable polysaccharide tablet for the treatment of mild to moderate and early stage COVID-19 Patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.

                            Product Name : ProLectin-M

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 08, 2023

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Alke Research Private Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ProLectin-I

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioxytran Receives Approval to Initiate Trials with ProLectin-I

                            Details : ProLectin-I binds to the ‘galectin fold’ of the spike protein thereby neutralizing a replication and ability of virus to infect other cells, it also binds to spike protein fragments thought to be the cause of ongoing inflammation. It is expected to t...

                            Product Name : ProLectin-I

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            June 02, 2023

                            Lead Product(s) : ProLectin-I

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BXT-25

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials

                            Details : BXT-25 is a intravenous version of hyperbaric oxygen treatment that lasts 9-18 hours and without any harmful side effects. It is a new paradigm in the way strokes and neurodegenerative diseases such as alzheimer’s, dementia, and traumatic brain injury ...

                            Product Name : BXT-25

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 19, 2023

                            Lead Product(s) : BXT-25

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients

                            Details : ProLectin-M having galactomannan, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases.

                            Product Name : ProLectin-M

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 12, 2022

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BXT-25

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bioxytran Seeking Partners for Late Stage Treatment of Coronavirus

                            Details : Bioxytran seeks to explore collaborations with international drug makers to treat patients at the end stage of Acute Respiratory Distress Syndrome affected with Wuhan Coronavirus.

                            Product Name : BXT-25

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            May 02, 2020

                            Lead Product(s) : BXT-25

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth